18-MC reduces methamphetamine and nicotine self-administration in ratsGlick, S D.1,2; Maisonneuve, I M.1; Dickinson, H A.1NeuroReport: June 26th, 2000 - Volume 11 - Issue 9 - p 2013–2015 NEUROPHARMACOLOGY Abstract Author InformationAuthors In previous studies, 18-methoxycoronaridine (18-MC), a novel iboga alkaloid congener, has been found to decrease the intravenous self-administration of morphine and cocaine in rats. In the present study, 18-MC (1–40 mg/kg, i.p.) dose–dependently decreased the i.v. self-administration of methamphetamine and nicotine. As in the previous studies, drug self-administration was reduced for ≥ 24 h after the highest dose of 18-MC. A comparison of 18-MC's interactions with all four drugs of abuse studied so far indicated that 18-MC is least effective in decreasing methamphetamine self-administration and most potent in decreasing nicotine self-administration. The results suggest that a nicotinic antagonist action of 18-MC contributes to its putative anti-addictive efficacy. 1Center for Neuropharmacology and Neuroscience, (MC-136), Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208, USA 2Corresponding Author: S. D. Glick Acknowledgements: This work was supported by NIDA grant DA 03817. Received 21 March 2000; accepted 11 April 2000 © 2000 Lippincott Williams & Wilkins, Inc.